Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination
暂无分享,去创建一个
[1] S. Elledge,et al. Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 , 2013, PLoS pathogens.
[2] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[3] T. Kepler,et al. Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.
[4] Robin A. Weiss,et al. Neutralizing antibodies to HIV-1 induced by immunization , 2013, The Journal of experimental medicine.
[5] J. McCluskey,et al. Tolerance through Indifference: Autoreactive B Cells to the Nuclear Antigen La Show No Evidence of Tolerance in a Transgenic Model 1 , 2003, The Journal of Immunology.
[6] M. Nussenzweig,et al. Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.
[7] M Anthony Moody,et al. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.
[8] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[9] D. Irvine,et al. Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry* , 2013, The Journal of Biological Chemistry.
[10] V. Pascual,et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors , 2008, Proceedings of the National Academy of Sciences.
[11] F. Pereyra,et al. A method for identification of HIV gp140 binding memory B cells in human blood. , 2009, Journal of immunological methods.
[12] H. Liao,et al. Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 , 2011, PloS one.
[13] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[14] D. Burton,et al. Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.
[15] D. Burton,et al. Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10 , 2013, The Journal of Immunology.
[16] R. Palacios,et al. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature , 2002, Lupus.
[17] D. Burton,et al. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.
[18] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[19] R. Hardy,et al. The site and stage of anti-DNA B-cell deletion , 1995, Nature.
[20] Renate Kunert,et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.
[21] J. Mascola,et al. Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 , 2013, Journal of Virology.
[22] C. Goodnow. Transgenic mice and analysis of B-cell tolerance. , 1992, Annual review of immunology.
[23] Jesús Santos,et al. Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. , 2013, AIDS research and human retroviruses.
[24] Yih-En Andrew Ban,et al. Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.
[25] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[26] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[27] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[28] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[29] J. Mascola,et al. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors , 2012, The Journal of Immunology.
[30] H. Liao,et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance , 2009, Proceedings of the National Academy of Sciences.
[31] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[32] H. Liao,et al. Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.
[33] M. Nussenzweig,et al. Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.
[34] B. Haynes,et al. Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies , 2014, The Journal of Immunology.
[35] Pojen P. Chen,et al. The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes1 , 2007, The Journal of Immunology.
[36] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[37] D. Burton,et al. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions , 2010, Proceedings of the National Academy of Sciences.
[38] M. McCarter,et al. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies , 2013, Proceedings of the National Academy of Sciences.
[39] B. Haynes,et al. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution , 2010, Proceedings of the National Academy of Sciences.
[40] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[41] H. Liao,et al. Stable Docking of Neutralizing Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Monoclonal Antibodies 2F5 and 4E10 Is Dependent on the Membrane Immersion Depth of Their Epitope Regions , 2009, Journal of Virology.
[42] R. Hardy. B-1 B Cell Development1 , 2006, The Journal of Immunology.
[43] T. Kepler,et al. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. , 2014, The Journal of clinical investigation.
[44] J. Mascola,et al. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.
[45] Vicki C. Ashley,et al. Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.
[46] Feng Gao,et al. Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.
[47] T. Kepler,et al. Somatic hypermutation in B cells: an optimal control treatment. , 1993, Journal of theoretical biology.
[48] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[49] B. Haynes,et al. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. , 2011, Current opinion in immunology.
[50] Ron Diskin,et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.
[51] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[52] D. Wallace,et al. False-positive human immunodeficiency virus testing in patients with lupus erythematosus. , 1993, Seminars in arthritis and rheumatism.
[53] M. Carrington,et al. Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection , 2007, Journal of Virology.
[54] D. Burton,et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 , 2010, Proceedings of the National Academy of Sciences.
[55] B. R. Kaye. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). , 1989, Annals of internal medicine.
[56] D. Huang,et al. HIV-1 gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression , 2013, Nature Immunology.
[57] M. Shlomchik,et al. Sites and stages of autoreactive B cell activation and regulation. , 2008, Immunity.
[58] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[59] H. Katinger,et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data , 2007, AIDS.
[60] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[61] Tongqing Zhou,et al. Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.
[62] D. Pisetsky,et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation , 1990, The Journal of experimental medicine.
[63] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[64] T. Nishikawa,et al. Auto-reactive B cells against peripheral antigen, desmoglein 3, escape from tolerance mechanism. , 2004, International immunology.
[65] Barney S. Graham,et al. Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.
[66] Lynn Morris,et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.
[67] J. Mascola,et al. Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region , 2009, Journal of Virology.
[68] M. Nussenzweig,et al. Autoreactivity in human IgG+ memory B cells. , 2007, Immunity.
[69] Eugene I. Shakhnovich,et al. Optimality of Mutation and Selection in Germinal Centers , 2010, PLoS Comput. Biol..
[70] Michael S. Seaman,et al. HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes , 2012, Journal of Virology.
[71] C. Goodnow,et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens , 1991, Nature.
[72] W. Blattner,et al. In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth , 2009, Journal of Virology.
[73] A. Fauci,et al. Insights into B cells and HIV‐specific B‐cell responses in HIV‐infected individuals , 2013, Immunological reviews.
[74] V. Stewart,et al. RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[75] Thomas B Kepler,et al. B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.
[76] T. Kepler,et al. Differential Reactivity of Germ Line Allelic Variants of a Broadly Neutralizing HIV-1 Antibody to a gp41 Fusion Intermediate Conformation , 2011, Journal of Virology.
[77] B. Haynes,et al. Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.
[78] R. Wyatt,et al. B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates , 2013, The Journal of Immunology.
[79] T. Kepler,et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. , 2009, Journal of virological methods.
[80] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[81] H. Liao,et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies , 2009, Proceedings of the National Academy of Sciences.
[82] N. Letvin,et al. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. , 2000, Archives of internal medicine.
[83] T. Kepler,et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies , 2013, The Journal of experimental medicine.
[84] S. Pillai,et al. Marginal zone B cells. , 2005, Annual review of immunology.
[85] J. Lifson,et al. Distribution and three-dimensional structure of AIDS virus envelope spikes , 2006, Nature.
[86] Jörn E. Schmitz,et al. Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection , 2009, PLoS medicine.
[87] James E. Crowe,et al. Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.
[88] T. Kepler,et al. Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.
[89] Danielle L. Watt,et al. Altered Ig Hypermutation Pattern and Frequency in Complementary Mouse Models of DNA Polymerase ζ Activity , 2012, The Journal of Immunology.
[90] Q. Sattentau,et al. Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. , 2012, Journal of AIDS & clinical research.
[91] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[92] N. Klinman,et al. Relative roles of somatic and darwinian evolution in shaping the antibody response , 2000, Immunologic research.
[93] Development of prophylactic vaccines against HIV-1 , 2013, Retrovirology.
[94] Leonardo Calza,et al. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy , 2003, International journal of STD & AIDS.
[95] S. Plotkin. Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.
[96] B. Haynes,et al. Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10 , 2013, The Journal of Immunology.
[97] V. Brusic,et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.
[98] Antonio Lanzavecchia,et al. Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.
[99] Hanqin Peng,et al. Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of gp41 , 2013, Journal of Virology.
[100] David Baltimore,et al. Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis , 2011, Nature.
[101] T. Kepler,et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated , 2011, The Journal of experimental medicine.
[102] D. Nemazee,et al. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes , 1989, Nature.
[103] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[104] M. Jackson,et al. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen , 1996, The Journal of experimental medicine.
[105] Gwo-Yu Chuang,et al. Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.
[106] H. Liao,et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. , 2012, Trends in microbiology.
[107] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.